Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

modified influenza virus expressing HPV16 E6/E7 FluBHPVE6E7

A cancer vaccine comprised of a modified influenza viral vector that lacks the C-terminal part of the non-structural gene NS1 (delNS) encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration, modified influenza virus expressing HPV16 E6/E7 FluBHPVE6E7 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. HPV16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:delNS influenza virus expressing HPV16 E6/E7 FluBHPVE6E7
FluBHPVE6E7
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search